Definiens Appoints Dr. Gerald Möller as Chairman of its Supervisory Board
|| Print ||
|Thursday, 15 November 2012 11:00 (UTC + 1)|
Munich, Germany, November 15, 2012 / B3C newswire / – Definiens AG, the leader in image analysis for Digital Pathology, today announced that Dr. Gerald Möller, has joined the company's supervisory board as an independent member and has been appointed chairman. Following the recent financing round, Dr. Möller will guide the expansion of Definiens’ current business and the development and commercialization of innovative products for clinical Digital Pathology.
Definiens’ image analysis solutions are currently deployed by all major biopharmaceutical companies, leading cancer centers and key pathology reference labs. Building on the leadership position in the life sciences sector, Definiens is rapidly growing its footprint in tissue based diagnostics, including the development of new companion diagnostic tests. These novel companion diagnostic tests will further accelerate the growth of Definiens’ business in Clinical Digital Pathology.
“I am very excited to join Definiens’ supervisory board at this defining point in time,” commented Gerald Möller. “Quantitative Digital Pathology will not be possible without image analysis as provided by Definiens. I am very much looking forward to working with the Definiens team to further expand the leadership position in image analysis for Digital Pathology and grow the business in companion diagnostics and Clinical Digital Pathology.”
Previously, Dr. Möller spent 23 years at Boehringer Mannheim in Germany, Japan and the US, where he held a number of leadership positions, including president of Decentralized Diagnostics, president of Advanced Diagnostics and Biochemicals, and CEO of Boehringer Mannheim Therapeutics. In 1995 he became CEO of the worldwide Boehringer Mannheim Group. Following the company's acquisition by Roche, Dr. Möller became head of Global Development and Strategic Marketing, Pharmaceuticals, and a member of the Executive Committee at Hoffmann LaRoche. In addition to Definiens, Dr. Möller is chairman of the board at Morphosys AG and sits on several further life sciences and diagnostics boards, including Illumina Inc., Bionostics Inc., and Vivacta Ltd. He also is chairman of the Foundation for Innovative New Diagnostics (FIND), a product development and implementation partnership financed in part by the Bill & Melinda Gates Foundation. He holds a Ph.D. in physical chemistry from the University of Kiel in Germany.
"We are delighted to have Dr. Möller as chairman of our board of directors. Gerald’s strong track record in the healthcare space and his unmatched expertise in advanced diagnostics will be invaluable as Definiens expands into Clinical Digital Pathology,” said Thomas Heydler, CEO of Definiens. “His commitment and vision will be instrumental to further strengthen Definiens as the leader in Quantitative Digital Pathology for life science research, tissue based companion diagnostics and clinical routine.”
Definiens is headquartered in Munich, Germany, and has offices throughout the United States. Further information is available at www.definiens.com.